BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 29531323)

  • 1. Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression.
    McClure BJ; Heatley SL; Kok CH; Sadras T; An J; Hughes TP; Lock RB; Yeung D; Sutton R; White DL
    Br J Cancer; 2018 Apr; 118(7):1000-1004. PubMed ID: 29531323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EP300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia.
    Hou Z; Ren Y; Zhang X; Huang D; Yan F; Sun W; Zhang W; Zhang Q; Fu X; Lang Z; Chu C; Zou B; Gao B; Jin B; Kang Z; Liu Q; Yan J
    Cell Commun Signal; 2024 Apr; 22(1):211. PubMed ID: 38566191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia.
    Zhao X; Wang P; Diedrich JD; Smart B; Reyes N; Yoshimura S; Zhang J; Yang W; Barnett K; Xu B; Li Z; Huang X; Yu J; Crews K; Yeoh AEJ; Konopleva M; Wei CL; Pui CH; Savic D; Yang JJ
    Nat Commun; 2022 Sep; 13(1):5401. PubMed ID: 36104354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EP300 through upregulating the expression of vimentin to promote the progression of chordoma.
    Wen L; Xie B; Li H; Huang J; Shi Y; Tao Y; Chen Y
    Neurosurg Focus; 2024 May; 56(5):E17. PubMed ID: 38691868
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Sadras T; Müschen M
    Blood Cancer Discov; 2020 Jul; 1(1):18-20. PubMed ID: 34661138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stem cell-like reprogramming is required for leukemia-initiating activity in B-ALL.
    Fregona V; Bayet M; Bouttier M; Largeaud L; Hamelle C; Jamrog LA; Prade N; Lagarde S; Hebrard S; Luquet I; Mansat-De Mas V; Nolla M; Pasquet M; Didier C; Khamlichi AA; Broccardo C; Delabesse É; Mancini SJC; Gerby B
    J Exp Med; 2024 Jan; 221(1):. PubMed ID: 37930337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The insertion/deletion polymorphism rs201494641 at
    Cafaro C; Ali Z; Lamarca A; Di Bello DT; Lozano LD; Ekdahl L; Thodberg M; Pertesi M; De Lapuente Portilla AL; Nilsson B
    Haematologica; 2024 May; ():. PubMed ID: 38721738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of EP300-ZNF384 fusion in patients with acute lymphoblastic leukemia using RNA fusion gene panel sequencing.
    Jing Y; Li YF; Wan H; Liu DH
    Ann Hematol; 2020 Nov; 99(11):2611-2617. PubMed ID: 32980888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort.
    Zaliova M; Stuchly J; Winkowska L; Musilova A; Fiser K; Slamova M; Starkova J; Vaskova M; Hrusak O; Sramkova L; Stary J; Zuna J; Trka J
    Haematologica; 2019 Jul; 104(7):1396-1406. PubMed ID: 30630978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis.
    Agraz-Doblas A; Bueno C; Bashford-Rogers R; Roy A; Schneider P; Bardini M; Ballerini P; Cazzaniga G; Moreno T; Revilla C; Gut M; Valsecchi MG; Roberts I; Pieters R; De Lorenzo P; Varela I; Menendez P; Stam RW
    Haematologica; 2019 Jun; 104(6):1176-1188. PubMed ID: 30679323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases.
    Li JF; Dai YT; Lilljebjörn H; Shen SH; Cui BW; Bai L; Liu YF; Qian MX; Kubota Y; Kiyoi H; Matsumura I; Miyazaki Y; Olsson L; Tan AM; Ariffin H; Chen J; Takita J; Yasuda T; Mano H; Johansson B; Yang JJ; Yeoh AE; Hayakawa F; Chen Z; Pui CH; Fioretos T; Chen SJ; Huang JY
    Proc Natl Acad Sci U S A; 2018 Dec; 115(50):E11711-E11720. PubMed ID: 30487223
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Passet M; Boissel N; Sigaux F; Saillard C; Bargetzi M; Ba I; Thomas X; Graux C; Chalandon Y; Leguay T; Lengliné E; Konopacki J; Quentin S; Delabesse E; Lafage-Pochitaloff M; Pastoret C; Grardel N; Asnafi V; Lhéritier V; Soulier J; Dombret H; Clappier E;
    Blood; 2019 Jan; 133(3):280-284. PubMed ID: 30510083
    [No Abstract]   [Full Text] [Related]  

  • 13. ZNF384-fusion proteins have high affinity for the transcriptional coactivator EP300 and aberrant transcriptional activities.
    Yamamoto H; Hayakawa F; Yasuda T; Odaira K; Minamikawa Y; Tange N; Hirano D; Kojima Y; Morishita T; Tsuzuki S; Naoe T; Kiyoi H
    FEBS Lett; 2019 Aug; 593(16):2151-2161. PubMed ID: 31234226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group.
    Hirabayashi S; Butler ER; Ohki K; Kiyokawa N; Bergmann AK; Möricke A; Boer JM; Cavé H; Cazzaniga G; Yeoh AEJ; Sanada M; Imamura T; Inaba H; Mullighan C; Loh ML; Norén-Nyström U; Pastorczak A; Shih LY; Zaliova M; Pui CH; Haas OA; Harrison CJ; Moorman AV; Manabe A
    Leukemia; 2021 Nov; 35(11):3272-3277. PubMed ID: 33692463
    [No Abstract]   [Full Text] [Related]  

  • 15. Caution encouraged in next-generation sequencing immunogenetic analyses in acute lymphoblastic leukemia.
    Abdo C; Thonier F; Simonin M; Kaltenbach S; Valduga J; Petit A; Brüggemann M; Macintyre E
    Blood; 2020 Aug; 136(9):1105-1107. PubMed ID: 32438392
    [No Abstract]   [Full Text] [Related]  

  • 16. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.
    Gu Z; Churchman ML; Roberts KG; Moore I; Zhou X; Nakitandwe J; Hagiwara K; Pelletier S; Gingras S; Berns H; Payne-Turner D; Hill A; Iacobucci I; Shi L; Pounds S; Cheng C; Pei D; Qu C; Newman S; Devidas M; Dai Y; Reshmi SC; Gastier-Foster J; Raetz EA; Borowitz MJ; Wood BL; Carroll WL; Zweidler-McKay PA; Rabin KR; Mattano LA; Maloney KW; Rambaldi A; Spinelli O; Radich JP; Minden MD; Rowe JM; Luger S; Litzow MR; Tallman MS; Racevskis J; Zhang Y; Bhatia R; Kohlschmidt J; Mrózek K; Bloomfield CD; Stock W; Kornblau S; Kantarjian HM; Konopleva M; Evans WE; Jeha S; Pui CH; Yang J; Paietta E; Downing JR; Relling MV; Zhang J; Loh ML; Hunger SP; Mullighan CG
    Nat Genet; 2019 Feb; 51(2):296-307. PubMed ID: 30643249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemia With
    Lin N; Yan X; Cai D; Wang L
    Front Oncol; 2021; 11():709036. PubMed ID: 34395283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prognostic Significance of
    Qin YZ; Jiang Q; Xu LP; Wang Y; Jiang H; Dao FT; Chen WM; Zhao XS; Liu YR; Zhang XH; Liu KY; Huang XJ
    Front Oncol; 2021; 11():632532. PubMed ID: 33816270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ZNF384-Related Fusion Genes in Acute Lymphoblastic Leukemia.
    Zhu L; Bai W; Cheng Q; Fang J
    Cancer Control; 2023; 30():10732748231182787. PubMed ID: 37306722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genetic basis and cell of origin of mixed phenotype acute leukaemia.
    Alexander TB; Gu Z; Iacobucci I; Dickerson K; Choi JK; Xu B; Payne-Turner D; Yoshihara H; Loh ML; Horan J; Buldini B; Basso G; Elitzur S; de Haas V; Zwaan CM; Yeoh A; Reinhardt D; Tomizawa D; Kiyokawa N; Lammens T; De Moerloose B; Catchpoole D; Hori H; Moorman A; Moore AS; Hrusak O; Meshinchi S; Orgel E; Devidas M; Borowitz M; Wood B; Heerema NA; Carrol A; Yang YL; Smith MA; Davidsen TM; Hermida LC; Gesuwan P; Marra MA; Ma Y; Mungall AJ; Moore RA; Jones SJM; Valentine M; Janke LJ; Rubnitz JE; Pui CH; Ding L; Liu Y; Zhang J; Nichols KE; Downing JR; Cao X; Shi L; Pounds S; Newman S; Pei D; Guidry Auvil JM; Gerhard DS; Hunger SP; Inaba H; Mullighan CG
    Nature; 2018 Oct; 562(7727):373-379. PubMed ID: 30209392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.